Enhanced expression of peroxisome proliferate-activated receptor gamma (PPAR-γ) in advanced prostate cancer

Anticancer Research

Volumn 32, Issue 8, 2012, Pages 3479-3484

  Rogenhofer, Sebastian ^a   Ellinger, Jörg ^a   Kahl, Philip ^b   Stoehr, Christine ^c   Hartmann, Arndt ^c   Engehausen, Dirk ^c   Wieland, Wolf Ferdinand ^d   Müller, Stefan C ^a   Hofstädter, Ferdinand ^d   Walter, Bernhard ^c  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^d UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Immunohistochemistry; Inflammation; Nuclear receptor PPAR gamma; Prostate cancer

Indexed keywords

CYCLOOXYGENASE 2; FARNESOID X RECEPTOR; INDUCIBLE NITRIC OXIDE SYNTHASE; LIVER X RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RETINOIC ACID RECEPTOR ALPHA; RETINOID X RECEPTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA;

ADVANCED CANCER; ARTICLE; CANCER SURGERY; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; PROSTATECTOMY; TISSUE MICROARRAY; TRANSURETHRAL RESECTION;

BASE SEQUENCE; CYCLOOXYGENASE 2; DNA PRIMERS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NITRIC OXIDE SYNTHASE TYPE II; ORPHAN NUCLEAR RECEPTORS; PPAR GAMMA; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; TISSUE ARRAY ANALYSIS;

EID: 84865682766     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J and Thun MJ: Cancer statistics, 2009. CA Cancer J Clin 59: 225-249, 2009.
2. Pienta KJ and Smith DC: Advances in prostate cancer chemotherapy: a new era begins. CA Cancer J Clin 55: 300-318, 2005.
3. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M and Tannock IF: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: Updated survival in the TAX 327 study. J Clin Oncol 26: 242-245, 2008.
4. De Dosso S and Berthold DR: Docetaxel in the management of prostate cancer: Current standard of care and future directions. Expert Opin Pharmacother 9(11): 1969-1979, 2008.
5. Walter B, Rogenhofer S, Vogelhuber M, Berand A, Wieland WF, Andreesen R and Reichle A: Modular therapy approach in metastatic castration-refractory prostate cancer. World J Urol. 28(6): 745-750, 2008.
6. Olefsky JM: Nuclear receptor minireview series. J Biol Chem 276(40): 36863-36864, 2001.
7. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, Blumberg B, Kastner P, Mark M, Chambon P and Evans RM; The nuclear receptor super family: The second decade. Cell 83(6): 835-839, 1995.
8. Ottow E and Weinmann H: Nuclear Receptors as Drug Targets: Methods and Principles in Medicinal Chemistry. Wiley VCH Verlag GmbH, Weinheim, Germany, 2008.
9. Lee JS, Kim KI and Baek SH: Nuclear receptors and coregulators in inflammation and cancer. Cancer Lett 267(2): 189-196, 2008.
10. Thacher SM, Vasudevan J and Chandraratna RA: Therapeutic applications for ligands of retinoid receptors. Curr Pharm Des 6(1): 25-58, 2000.
11. Altucci L, Leibowitz MD, Ogilvie KM, de Lera AR and Gronemeyer H: RAR and RXR modulation in cancer and metabolic disease. Nat Rev Drug Discov 6(10): 793-810, 2007.
12. Mohan R and Heyman RA: Orphan nuclear receptor modulators. Curr Top Med Chem 3(14): 1637-1647, 2003.
13. Bełtowski J and Semczuk A: Liver X receptor (LXR) and the reproductive system - a potential novel target for therapeutic intervention. Pharmacol Rep 62(1): 15-27, 2012
14. Chuu CP, Kokontis JM, Hiipakka RA and Liao S: Modulation of liver X receptor signaling as novel therapy for prostate cancer. J Biomed Sci 14(5): 543-553, 2007.
15. Kaeding J, Bouchaert E, Belanger J, Caron P, Chouinard S, Verreault M, Larouche O, Pelletier G, Staels B, Belanger A and Barbier O: Activators of the farnesoid X receptor negatively regulate androgen glucuronidation in human prostate cancer LNCAP cells. Biochem J 410: 245-253, 2008.
16. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987 (in German).
17. Read WL, Baggstrom MQ, Fracasso PM and Govindan R: A phase I study of bexarotene and rosiglitazone in patients with refractory cancers. Chemotherapy 54(3): 236-241, 2008.
18. Segawa Y, Yoshimura R, Hase T, Nakatani T, Wada S, Kawahito Y, Kishimoto T and Sano H. Expression of peroxisome proliferator-activated receptor (PPAR) in human prostate cancer. Prostate 51(2): 108-116, 2002.
19. Nakamura Y, Suzuki T, Sugawara A, Arai Y and Sasano H: Peroxisome proliferator-activated receptor gamma in human prostate carcinoma. Pathol Int 59: 288-293, 2009.
20. Nagata D, Yoshihiro H, Nakanishi M, Naruyama H, Okada S, Ando R, Tozawa K and Kohri K: Peroxisome proliferator-activated receptor-gamma and growth inhibition by its ligands in prostate cancer. Cancer Detect Prev 32(3): 259-266, 2008.
21. Alfaro JM, Fraile B, Lobo MV, Royuela M, Paniagua R and Arenas MI. Immunohistochemical detection of the retinoid X receptors alpha, beta, and gamma in human prostate. J Androl 24(1): 113-119, 2003.
22. Richter F, Joyce A, Fromowitz F, Wang S, Watson J, Watson R, Irwin RJ Jr., Huang HF: Immunohistochemical localization of the retinoic acid receptors in human prostate. J Androl 23(6): 830-838, 2002.
23. Gyftopoulos K, Sotiropoulou G, Varakis I and Barbalias GA. Cellular distribution of retinoic acid receptor-alpha in benign hyperplastic and malignant human prostates: comparison with androgen, estrogen and progesterone receptor status. Eur Urol 38(3): 323, 2000.
24. Ghosh N, Chaki R, Mandal V and Mandal SC: COX-2 as a target for cancer chemotherapy. Pharmacol Rep 62(2): 233-244, 2010.
25. Pruthi RS, Derksen JE and Moore D: A pilot study of use of the cyclooxygenase-2 inhibitor celecoxib in recurrent prostate cancer after definitive radiation therapy or radical prostatectomy. BJU Int 93: 275-278, 2004.
26. Gupta S, Srivastava M, Ahmad N, Bostwick DG and Mukhtar H: Overexpression of cyclooxygenase-2 in human prostate adenocarcinoma. Prostate 42(1): 73-78, 2000.
27. Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH and Levine AC: Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology 56(4): 671-676, 2000.
28. Mantovani A, Allavena P, Sica A and Balkwill F: Cancer-related inflammation. Nature 454(7203): 436-444, 2008.
29. Meyer S, Vogt T, Landthaler M, Berand A, Reichle A, Bataille F, Marx AH, Menz A, Hartmann A, Kunz-Schughart LA and Wild PJ: Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma. PPAR Res 848645, 2009.
30. Kolár Z, Murray PG, Madarova J, Lukesova M, Hlobilkova A, Rihαkovα P, Flavell P, Strnad M, Student V and Vojtesek B: Nuclear receptors in early hormone-refractory prostate cancer and their relationship to apoptosis-related proteins. Neoplasma 49(3): 172-177, 2002.